Allied Journal of Medical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Allied Journal of Medical Research (2025) Volume 9, Issue 3

Biologyâ??s advancements reshape treatment and diagnosis

Hye-Jin Park*

Department of Biomedical Sciences, Seoul National University, Seoul, South Korea

*Corresponding Author:
Hye-Jin Park
Department of Biomedical Sciences
Seoul National University, Seoul, South Korea.
E-mail: hyejin.park@snu.ac.kr

Received : 01-Sep-2025, Manuscript No. aaajmr-25; Editor assigned : 03-Sep-2025, PreQC No. aaajmr-25(PQ); Reviewed : 23-Sep-2025, QC No aaajmr-25; Revised : 02-Oct-2025, Manuscript No. aaajmr-25(R); Published : 13-Oct-2025 , DOI : 10.35841/aaajmr-9.3.295

Citation: Park H. Biology's advancements reshape treatment and diagnosis. aaajmr. 2025;09(03):295.

Visit for more related articles at Allied Journal of Medical Research

Introduction

This paper talks about the newest ways CRISPR-Cas9 is being used for cancer treatment. It highlights how the technology can precisely target genes critical for tumor growth and spread, discussing strategies like editing immune cells to boost anti-cancer responses and directly modifying cancer cells to make them self-destruct. The authors also weigh in on ongoing challenges, such as unintended off-target edits and effective delivery methods, and share their outlook on future clinical applications[1].

This article explores the exciting potential of mRNA technology beyond vaccines for infectious diseases. It outlines how mRNA can be engineered to treat cancer, genetic disorders, and autoimmune diseases by instructing cells to produce therapeutic proteins. The discussion includes breakthroughs in mRNA delivery systems and the challenges of stability and specific targeting, offering a glimpse into future clinical applications[2].

this review explains how artificial intelligence is changing how we find and develop new medications. It covers everything from identifying potential drug candidates and predicting their efficacy to optimizing molecular structures and streamlining clinical trials. The authors point out the immense efficiency gains but also acknowledge the hurdles in data quality and algorithmic bias, suggesting future directions for integrating Artificial Intelligence more deeply[3].

This piece discusses the growing use of organoids as models for studying human diseases. these miniature, lab-grown organs, which mimic native tissues, are providing unprecedented insights into development, disease progression, and drug responses. The paper details their application in understanding neurological disorders, cancer, and infectious diseases, while also addressing their limitations and the path forward for more complex and vascularized organoid systems[4].

This review delves into the progress of gene therapy for neurological disorders. It explains how delivering therapeutic genes can correct underlying genetic defects or introduce beneficial proteins to slow or reverse the progression of conditions like Alzheimer's, Parkinson's, and Huntington's disease. The authors emphasize the breakthroughs in viral vector development and targeted delivery, alongside the persistent challenges of safety and widespread application[5].

This paper showcases the latest advancements in cancer immunotherapy, specifically focusing on CAR T-cell therapies and immune checkpoint inhibitors. It clarifies how these treatments empower the body's own immune system to fight cancer, leading to significant clinical responses in various malignancies. The authors discuss optimization strategies to overcome resistance, manage side effects, and expand these therapies to a broader patient population[6].

the microbiome's influence on health and disease, as this article does. It highlights the complex interplay between gut microbes and human physiology, impacting everything from metabolism and immunity to mental health. The paper delves into how dysbiosis (an imbalance) can contribute to conditions like inflammatory bowel disease, obesity, and even neurological disorders, proposing microbiome-targeted interventions as future therapeutic avenues[7].

This research explains how biofabrication and 3D printing are revolutionizing regenerative medicine. It details the creation of functional tissues and organs from biological materials, layer by layer, addressing the critical shortage of donor organs. The authors discuss the intricacies of bioprinting complex structures with living cells, supporting blood vessels, and nervous systems, outlining both current achievements and future challenges in clinical translation[8].

This publication provides an overview of single-cell genomics, a technology that allows scientists to study the genetic material of individual cells rather than bulk cell populations. It reveals unprecedented insights into cellular heterogeneity, rare cell types, and dynamic cellular processes crucial for understanding disease mechanisms, particularly in cancer and developmental biology. The paper also touches on the ongoing improvements in resolution and throughput that are expanding its utility[9].

This article looks at the exciting field of epigenetic therapies and how they're being used to treat various diseases. It explains that epigenetics involves changes in gene expression without altering the DNA sequence itself, and how targeting these mechanisms can effectively treat cancers, inflammatory conditions, and even neurological disorders. The authors highlight the development of novel epigenetic drugs and the promise they hold, while also acknowledging the need for more specific and less toxic compounds[10].

 

Conclusion

Recent advancements across biological sciences are profoundly transforming disease treatment and diagnosis. Gene editing with CRISPR-Cas9 is finding innovative uses in cancer therapy, allowing precise targeting of tumor growth-critical genes and boosting anti-cancer immune responses. Beyond infectious disease vaccines, mRNA technology shows exciting potential for treating cancers, genetic disorders, and autoimmune diseases by instructing cells to produce therapeutic proteins. Artificial Intelligence (AI) is rapidly changing drug discovery, improving efficiency from identifying potential drug candidates and predicting their efficacy to optimizing molecular structures and streamlining clinical trials. Lab-grown organoids are proving invaluable as models for studying human diseases, offering unprecedented insights into development, disease progression, and drug responses across various conditions. Gene therapy itself is seeing significant progress for neurological disorders, delivering therapeutic genes to correct defects or introduce beneficial proteins for conditions like Alzheimer's and Parkinson's. In the realm of immune-based treatments, cancer immunotherapy, including CAR T-cell therapies and immune checkpoint inhibitors, empowers the body's own immune system to fight cancer, leading to significant clinical responses. Research into the microbiome reveals its deep impact on health and disease, highlighting the complex interplay between gut microbes and human physiology, with implications for inflammatory and neurological disorders. Biofabrication and 3D printing are revolutionizing regenerative medicine by enabling the creation of functional tissues and organs from biological materials. Single-cell genomics provides unprecedented views into cellular heterogeneity and dynamic processes, crucial for understanding disease mechanisms, particularly in cancer and developmental biology. Lastly, epigenetic therapies are emerging, targeting gene expression changes without altering DNA sequences to effectively treat cancers, inflammatory conditions, and neurological disorders, promising novel drug development. These diverse fields collectively push the boundaries of medical science, offering new and precise therapeutic avenues for a wide range of complex diseases, while also addressing ongoing challenges in delivery, safety, and targeting.

References

  1. Meng W, Bo Y, Lingling D. CRISPR-Cas9-mediated gene editing in cancer therapy: Recent advances and future perspectives. Cancer Biol Med. 2023;20(6):441-457.

    2. Indexed at, Google Scholar, Crossref

  2. Rados?aw K, Muhammad M, Jasim A. mRNA-Based Therapeutics and Vaccines: Challenges and Advances. Cells. 2021;10(9):2267.

    3. Indexed at, Google Scholar, Crossref

  3. Kun L, Hongbo C, Wei S. Artificial intelligence for drug discovery. Drug Discov Today. 2023;28(1):103441.

    4. Indexed at, Google Scholar, Crossref

  4. Yiming L, Qingying Y, Mengjuan L. Organoids: From basic biology to applications in disease modeling. Biomed Res Int. 2022;2022(None):1571520.

    5. Indexed at, Google Scholar, Crossref

  5. Mitsuaki N, Hisashi A, Akira H. Gene therapy for neurological disorders: recent advances and prospects. Brain Regen. 2023;8(1):16.

    6. Indexed at, Google Scholar, Crossref

  6. Chao T, Chenxi S, Tian Q. Recent Advances in Cancer Immunotherapy. Adv Sci (Weinh). 2021;8(18):e2101341.

    7. Indexed at, Google Scholar, Crossref

  7. Bin W, Rui S, Haotian L. Microbiome and Health: What We Know and What's Next. Front Nutr. 2022;9(None):856417.

    8. Indexed at, Google Scholar, Crossref

  8. Seongjun L, Inyoung C, Youngin L. Recent progress in 3D bioprinting for regenerative medicine. J Biomed Mater Res B Appl Biomater. 2021;109(2):207-227.

    9. Indexed at, Google Scholar, Crossref

  9. Shuang Z, Xianmei S, Bin S. Single-cell genomics: recent advances and clinical applications. Front Cell Dev Biol. 2022;10(None):987154.

    10. Indexed at, Google Scholar, Crossref

  10. Hannah P, Ben Y, Shao JT. Advances in Epigenetic Therapies. J Med Chem. 2023;66(14):9531-9556.

    11. Indexed at, Google Scholar, Crossref

Get the App